Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment

BACKGROUND: Bortezomib is a proteasome inhibitor with minimal clinical activity as a monotherapy in solid tumours, but its combination with other targeted therapies is being actively investigated as a way to increase its anticarcinogenic properties. Here, we evaluate the therapeutic potential of co-...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Taylor-Harding, B, Agadjanian, H, Nassanian, H, Kwon, S, Guo, X, Miller, C, Karlan, B Y, Orsulic, S, Walsh, C S
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2012
Teme:
Translational Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3261668/
https://ncbi.nlm.nih.gov/pubmed/22166800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.546
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items